Skip to content
  • Home
  • Journalists
    • Headlines
  • Community
    • Businesses
    • Jobs
    • Learning
    • Marketplace
  • Store
(@)

Eli Lilly Trial Finds Alzheimer’s Drug Can Slow Progress of Disease

Donanemab is not a cure and comes with significant side effects, but patients had longer periods of independent living while on the drug.

Gina Kolata
Author: Gina Kolata

Written by

Gina Kolata

in

Drugs (Pharmaceuticals), Eli Lilly and Company, Research
←FTC Seeks ‘Blanket’ Ban on Meta’s Use of Young Users’ Data
Trump’s New Anti-Biden Ad Has One Problem: It Shows Photos From His Own Presidency→

More posts

  • Protesters, leaders push back against DHS over Newark detention facility conditions

  • Goldman and Lander spar hard over Israel

  • Snowflake climbs after Q1 results top expectations, guidance gets a boost

  • Synopsys drops despite better than expected Q2 results, big boost to full-year guidance

About Us


Support Us

Trademark & Copyright 1998 – 2025 · MOSAEC

  • Facebook
  • Instagram
  • LinkedIn
  • YouTube